Research programme: decoy receptors - BriaCell Therapeutics
Alternative Names: decoy receptors - BriaCell TherapeuticsLatest Information Update: 28 Jul 2024
At a glance
- Originator BriaCell Therapeutics Corp
- Class Antivirals
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in COVID-2019-infections in Canada
- 24 Jun 2020 BriaCell files a provisional patent application with the US PTO for “Multi-valent decoy receptors for diagnosis and/or treatment of coronavirus infection”
- 24 Jun 2020 Early research in COVID-2019 infections in Canada